BioAtla has been granted a patent for a polypeptide that binds to Ror2 protein, along with antibodies and fragments containing the polypeptide. The patent covers pharmaceutical compositions and kits containing these components. GlobalData’s report on BioAtla gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights BioAtla Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on BioAtla, Personalized cancer vaccines was a key innovation area identified from patents. BioAtla's grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

Antibody binding to ror2 protein

Source: United States Patent and Trademark Office (USPTO). Credit: BioAtla Inc

A recently granted patent (Publication Number: US11879011B2) discloses a human or humanized antibody or antibody fragment that specifically binds to the ROR2 protein. The antibody comprises a heavy chain variable region with three complementarity determining regions and a light chain variable region with specific amino acid sequences. Importantly, the antibody demonstrates a higher binding affinity to the ROR2 protein in a tumor microenvironment compared to a non-tumor microenvironment, with specific pH ranges identified for each. The patent also covers immunoconjugates containing the antibody and various agents like chemotherapeutic agents, radioactive atoms, cytostatic agents, and cytotoxic agents.

Furthermore, the patent includes claims for pharmaceutical compositions containing the immunoconjugates and a pharmaceutically acceptable carrier. Methods of treating cancer by administering these compositions to patients with ROR2 expressing cancer are also outlined in the patent. The disclosed immunoconjugates and pharmaceutical compositions offer a targeted approach to treating cancer by leveraging the specific binding affinity of the antibody to the ROR2 protein in tumor microenvironments, potentially enhancing treatment efficacy for patients with ROR2 expressing cancer.

To know more about GlobalData’s detailed insights on BioAtla, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies